Ledraxen (Enoxaparin Sodium)

Ledraxen (enoxaparin sodium) is used in the management of venous thromboembolism and related conditions.

• Deep vein thrombosis (DVT): prevention of clot formation in at‑risk patients and treatment of established thrombosis.
• Pulmonary embolism (PE): prevention of embolic events and treatment of confirmed emboli.
• Haemodialysis anticoagulation: maintains circuit patency by preventing clot formation during dialysis sessions.

• Enoxaparin sodium enhances the activity of antithrombin III, a natural inhibitor of coagulation factors. By binding to antithrombin, it accelerates the inhibition of factor Xa and, to a lesser extent, thrombin (factor IIa), thereby reducing thrombin generation and fibrin clot formation. This selective inhibition provides anticoagulant effect with a more predictable pharmacokinetic profile than unfractionated heparin.

The most frequently reported reactions to enoxaparin sodium involve bleeding and injection‑site symptoms, while rare events can be severe.

Common Side Effects

• Bruising or hematoma at injection site: localized bleeding under the skin.
• Minor bleeding: such as gum bleeding, epistaxis, or easy bruising.
• Nausea: mild gastrointestinal discomfort.
• Headache: transient mild headache.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening internal or external bleeding.
• Thrombocytopenia (including heparin‑induced thrombocytopenia): sudden drop in platelet count.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

When using Ledraxen, clinicians should consider several safety factors to minimize bleeding risk and ensure appropriate use.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Concomitant anticoagulants or antiplatelet agents: increased risk of bleeding; use with caution.
• Recent or planned surgery: assess bleeding risk and possibly discontinue before procedures.
• Pregnancy and lactation: safety data are limited; weigh benefits against potential risks.
• Elderly patients: monitor closely for bleeding due to age‑related pharmacodynamic changes.
• Store at controlled room temperature: keep in original packaging, protect from moisture and light.

Enoxaparin sodium may interact with other medicines that affect hemostasis or renal clearance.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulant effect.
• Antiplatelet drugs (aspirin, clopidogrel, ticagrelor): heightened bleeding risk.
• Fibrinolytic agents (alteplase, streptokinase): synergistic increase in hemorrhage.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): impair platelet function and raise bleeding potential.
• Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely)

• Certain antibiotics (e.g., quinolones, macrolides): may alter platelet activity.
• ACE inhibitors or diuretics: potential impact on renal function affecting drug clearance.
• Statins (especially high‑dose): rare reports of increased bleeding; monitor labs.